GXI.DE Stock Analysis
GX
Avoid
Based on Eyestock quantitative analysis, GXI.DE`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Gerresheimer AG manufactures and supplies glass and plastic products for the pharmaceutical and healthcare industry. The company is headquartered in Dusseldorf, Nordrhein-Westfalen and currently employs 11,062 full-time employees. The company went IPO on 2007-06-11. The company operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The firm operates approximately 40 production facilities in Europe, North America, South America and Asia.